Últimas noticias sobre ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution Multi-Sector ETF

Healthcare

Other

Technology

Financial Services

The Fund is an actively managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80 percent of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics* revolution (Genomics Revolution Companies). Under normal circumstances, substantially all of the Funds assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Funds investments will include micro-, small-, medium- and large-capitalization companies. The Funds investments in foreign equity securities will be in both developed and emerging markets.

Twist Bioscience Corp.

Caredx

Crispr Therapeutics Ag

Recursion Pharmaceuticals, Inc.

Ionis Pharmaceuticals Inc

Intellia Therapeutics

Beam Therapeutics Inc

Schrodinger, Inc.

Adaptive Biotechnologies Corporation

10X Genomics Inc

ARK Genomic Revolution ETF

Trump’s Economic Gambit Sparks Fierce Debate As Cathie Wood Sees A Reagan-Style Boom, Obama Adviser Calls Musk’s Role A ‘Performance Art’

Equities

News

Markets

ETFs

ARKG

ARKK

ARKW

GTLB

Ark Invest realizó compras millonarias de Tempus AI y GitLab tras sus informes de ganancias. ¿Qué impulsó estas decisiones estratégicas?

Tempus AI y GitLab: ¿Por qué Ark Invest compró acciones tras sus resultados financieros?

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

COIN

El martes, Ark Invest, firma liderada por Cathie Wood, realizó movimientos estratégicos en su portafolio, destacándose la compra de acciones de Tempus AI Inc. (NASDAQ:TEM) y Coinbase Global Inc.

Inversiones de Ark Invest: compras millonarias en Coinbase y ventas estratégicas en el ETF de Bitcoin

Ejecutivos de Tempus AI vendieron acciones por 20,3M$ tras el impresionante repunte del valor. ¿Qué implica esto para la empresa?

¿Por qué los ejecutivos de Tempus AI (TEM) vendieron acciones tras su increíble subida?

Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.32 by 25 percent. This is a 766.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $251.000 million which beat the analyst consensus estimate of $249.197 million by 0.72 percent. This is a 30.09 percent increase over sales of $192.948 million the same period last year.

Earnings

Earnings Beats

SMTC

Semtech Q4 2025 Adj. EPS $0.40 Beats $0.32 Estimate, Sales $251.000M Beat $249.197M Estimate

Guidance

ULTA

Ulta Beauty Expects FY25 Net Sales Of $11.5B - $11.6B (Est $11.67B), Comparable Sales Growth Of 0% - 1%, EPS Of $22.50 - $22.90 (Est $23.50)

EVCM

EverCommerce Sees Q1 Revenue $138M-$141M vs $174.667M Est., Sees FY25 Revenue $581M-$601M vs $723.177M Est.

Initiates Review Following Receipt of Expressions of Interest
Returned to Positive Adjusted EBITDA and Positive Cash Flow Generation in Fourth Quarter 2024 and Expanded Credit Facility, Enabling Enhanced Financial Flexibility
LEHI, Utah, March 13, 2025 /PRNewswire/ --&nbsp;Purple Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure&#x2122; Mattress," today announced that its Board of Directors (the "Board") has initiated a review of strategic alternatives for the Company, following inbound expressions of interest. The Board will consider a broad range of opportunities to maximize shareholder value, including, but not limited to, a sale, merger, or other strategic or financial transaction.
To evaluate potential alternatives for the Company, the Board has formed a special committee of independent directors comprised of Gary T. DiCamillo (Chair), D. Scott Peterson, and Claudia Hollingsworth.

Management

PRPL

Purple Innovation Announces Review Of Strategic Alternatives To Maximize Shareholder Value; Board Will Consider A Broad Range Of Opportunities To Maximize Shareholder Value, Including, But Not Limited To, A Sale, Merger, Or Other Strategic Or Financial Transaction.

aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 28 percent increase over losses of $(0.25) per share from the same period last year.

ATYR

aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate

JP Morgan analyst Mark Murphy maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Overweight and lowers the price target from $580 to $540.

Price Target

Analyst Ratings

ADBE

JP Morgan Maintains Overweight on Adobe, Lowers Price Target to $540

WIIM

RBRK

Rubrik shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.

PagerDuty Sees Q1 2026 Revenue $118M-$120M Vs $121.75M Estimate; Sees Adj. EPS $0.18-$0.19 Vs $0.20 Estimate

BYRN

Byrna Begins U.S. Ammo Production

Rubrik Sees Q1 Adj. EPS $(0.33)-$(0.31) Vs $(0.40) Est; Revenue $259M-$261M Vs $243.2M Est.

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.01 by 1900 percent. This is a 76 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $14.45 million which missed the analyst consensus estimate of $28.99 million by 50.17 percent. This is a 13.68 percent increase over sales of $12.71 million the same period last year.

Earnings Misses

JYNT

Joint Q4 EPS $(0.18) Misses $0.01 Estimate, Sales $14.45M Miss $28.99M Estimate

GRWG

GrowGenereration Sees FY25 Revenue $170M-$180M Vs $186.256M

EverCommerce Q4 2024 GAAP EPS $(0.07) Misses $(0.01) Estimate, Sales $175.000M Beat $170.436M Estimate

PLTR

Palantir Says Six New Customers Deploying Warp Speed To Accelerate On-shore Manufacturing Capabilities

SKLZ

Skillz Q4 2024 GAAP EPS $(1.50) Misses $(1.13) Estimate, Sales $20.400M Miss $25.053M Estimate

Mirion Joins Nuclear Energy Institute, American Nuclear Society's Trustees Of Nuclear Program

PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by 37.5 percent. This is a 29.41 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $121.40 million which beat the analyst consensus estimate of $119.77 million by 1.36 percent. This is a 9.25 percent increase over sales of $111.12 million the same period last year.

PagerDuty Q4 2025 Adj EPS $0.22 Beats $0.16 Estimate, Sales $121.40M Beat $119.77M Estimate

Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.14) by 50 percent. This is a 53.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $128.97 million which missed the analyst consensus estimate of $129.39 million by 0.32 percent. This is a 11.62 percent decrease over sales of $145.94 million the same period last year.

Purple Innovation Q4 Adj $(0.07) Beats $(0.14) Estimate, Sales $128.97M Miss $129.39M Estimate

Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) reported quarterly earnings of $1.60 per share. This is a 15900 percent increase over earnings of $0.01 per share from the same period last year. The company reported $18.93 million in sales this quarter. This is a 38.01 percent increase over sales of $13.71 million the same period last year.

FEIM

Frequency Electronics Q3 EPS $1.60 Up From $0.01 YoY, Sales $18.93M Up From $13.71M YoY

GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) reported quarterly sales of $37.436 million which missed the analyst consensus estimate of $40.412 million by 7.36 percent. This is a 24.30 percent decrease over sales of $49.452 million the same period last year.

GrowGeneration Q4 Sales $37.436M Miss $40.412M Estimate

Comments

ARK Genomic Revolution ETF

Noticias

Últimas noticias sobre ARK Genomic Revolution ETF (BATS:ARKG)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL